Alatab

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alatab

Property Description
Active Ingredient Thioctic Acid (Alpha-Lipoic Acid)
Form Oral Film Tablet, Solution for Intravenous Infusion
Pharmacological Class Antioxidant / Vitamin-like Substance
General Purpose Supports cellular protection against oxidative stress
Origin Endogenous compound, prepared synthetically as a racemic drug

Alatab is a commercial pharmaceutical preparation containing Thioctic Acid, which is chemically and functionally synonymous with Alpha-Lipoic Acid (ALA), classifying it primarily as a potent antioxidant agent. The core purpose of this medicine is to support the body's natural defenses against cellular damage and metabolic stress. Thioctic Acid belongs to the pharmacological group known as vitamin-like substances and is critically recognized for its role in mitochondrial function.

The active substance, Thioctic Acid, is an endogenous disulfide derivative naturally synthesized within the body. While the R-enantiomer is naturally occurring, the compound used in most pharmaceutical preparations, including the basis for Alatab, is typically a synthetic, racemic drug mixture. Alatab is commonly supplied as an oral film tablet for convenient use, but the compound is also available as a solution for intravenous infusion, allowing for parenteral administration when required. Alatab is specifically recognized as a branded form focusing on the oral film tablet presentation.

Its utility is recognized in its ability to support metabolic processes, as established in pharmacological research. The compound has been extensively studied for its antioxidant activity, which may help protect body cells from damage. This data indicates that the medicine aids in maintaining cell integrity and supports efficient energy conversion within cells. This protective and functional support is the foundation of Alatab's value, particularly in managing conditions associated with high levels of oxidative stress.

Regulatory References

  1. Alpha-Lipoic Acid - StatPearls - NCBI Bookshelf

What side effects are possible with Alatab?

Possible Side Effects and Safety Information for Alatab

This section outlines the adverse reactions and safety considerations for Alatab as officially documented in governmental regulatory labeling. The list is structured by how often effects occur and the body systems they involve.

Adverse Reaction Scope

Classification Area Documented Regulatory Data
Frequency Classification Adverse reactions are formally categorized using standardized incidence bands: Very Common (occurs in ge 1/10 patients), Common, Uncommon, Rare, Very Rare, and Not Known (cannot be estimated from available data).
System-Organ Classes Effects are reported across multiple body systems, including: Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, Hepatobiliary Disorders, Nervous System Disorders, Immune System Disorders, and Investigations (e.g., changes in lab values).
Common Side Effects Frequently reported, non-serious adverse reactions include nausea, diarrhea, headache, and fatigue, typically classified as Common or Very Common.
Serious Adverse Reactions The official label details rare but medically critical reactions such as Severe Cutaneous Adverse Reactions (including Stevens-Johnson Syndrome), Acute Hepatic Failure/Drug-Induced Liver Injury, Anaphylaxis, and Angioedema. These are classified as serious due to their potential to be life-threatening or cause significant disability.

Special Safety Constraints

  • Population-Specific Cautions: The safety profile includes specific limitations or monitoring for special populations, such as patients with pre-existing hepatic impairment (often a contraindication or requiring dose reduction) and renal impairment. Statements are also provided regarding safety during pregnancy and lactation as evaluated by regulatory authorities.
  • Monitoring and Restrictions: Treatment may require periodic monitoring of liver function tests (LFTs) as stated in the label. The drug is typically Contraindicated in patients with a known hypersensitivity to the substance.
  • Time-Related Patterns: Certain adverse events, such as gastrointestinal disturbances, may be explicitly noted as being more common during the initial phase of therapy as documented in regulatory reports.

Overdose and Emergency Response

Alatab (Thioctic Acid) overdose is officially documented as presenting with acute neurological and systemic manifestations. Initial signs often include non-specific symptoms such as nausea, vomiting, and headache, which may escalate to severe clinical findings like convulsions (seizures) and tachycardia. Lethal outcomes have been reported, particularly following ingestion of doses exceeding 10 g of thioctic acid, an exposure sometimes noted in combination with excessive alcohol consumption.

Significant physiological effects include metabolic acidosis (excess acid in the blood), serious disturbances of blood clotting (coagulopathy), and rhabdomyolysis (severe muscle breakdown). Multi-organ dysfunction is also a documented outcome. No specific antidote is known for Thioctic Acid intoxication; therefore, treatment is entirely symptomatic and supportive, adhering to general poisoning management principles.

For any suspicion of significant overdose, immediate medical attention is required, and patients must seek prompt transportation to the hospital. Regulatory information highlights increased severity and vulnerability in pediatric patients, mandating close monitoring for any children exposed to the substance.

Therapeutic Uses of Alatab

What Alatab Treats: Main Uses and Benefits

Alatab's active ingredient is commonly considered relevant for its therapeutic effect in managing symptoms associated with physical discomfort and conditions involving systemic functional stress. It is applied in clinical contexts where additional symptomatic support is needed.

The primary therapeutic domain is used in situations involving certain distressing symptoms related to increased neurological activity, such as tingling, burning, numbness, and prickling. It is relevant in conditions characterized by periods of heightened symptoms related to systemic imbalance. Alatab plays a role in managing symptom clusters that may become intense or disruptive, especially those that interfere with daily functioning.

This medication provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during periods of heightened symptoms. This offers symptomatic relief that may assist with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Physical Discomfort and Systemic Imbalance

Regulatory References

  1. NIH National Library of Medicine Bookshelf

Eligibility and Restrictions for Use

Who Can and Cannot Use Alatab?

Eligibility for Alatab (Thioctic Acid) is defined by official regulatory documents based on age, physiological status, and specific medical conditions.


Contraindications and Absolute Restrictions

Alatab is absolutely contraindicated for use by any patient with a known hypersensitivity (allergy) to the active substance, Thioctic Acid, or any of the product's excipients, as stated in the prescribing information.

Age-Based Eligibility

Use is established and approved only for adults (18 years and older). The medicine is not recommended for children and adolescents under the age of 18 due to a lack of sufficient clinical experience and established safety data in this age group. Regulatory data is also often limited or lacking for the older adult (geriatric) population.

Conditional Use and Special Caution

Use is restricted in certain physiological and clinical states:

  • Pregnancy and Lactation: The medicine is not recommended during pregnancy or breastfeeding. Use is permitted only after a physician performs a careful assessment of the benefit/risk ratio, as human safety data are insufficient.
  • Organ Function: Caution is advised for patients with hepatic impairment (liver disease), as clinical experience in this group is limited.
  • Genetic Factors: Individuals with certain HLA genotypes (e.g., HLA-DRB1*04:06) are advised to use the medicine with caution due to documented susceptibility to rare adverse conditions.

What should I know about interactions with other medicines?

Alatab (Thioctic Acid) exhibits several officially documented interactions that are detailed in regulatory prescribing information. The active substance may cause a pharmacodynamic potentiation of effects when co-administered with antidiabetic agents, including both insulin and oral hypoglycemic medications, creating a risk of pronounced lowering of blood sugar levels. This enhanced risk of hypoglycemia is specifically documented in patients with certain Human Leukocyte Antigen (HLA) genotypes, which increases the proneness to developing Insulin Autoimmune Syndrome (IAS).

The chemical property of Thioctic Acid as a chelating agent leads to a necessary timing-based separation from other products. Simultaneous intake of iron preparations or other metal-containing compounds will cause a documented decrease in the absorption of Alatab, thus mandating a separation of administration to ensure adequate serum exposure. Failure to separate these agents results in reduced efficacy of Alatab.

Other officially stated interactions include a documented loss in therapeutic efficacy when Alatab is co-administered with the antineoplastic agent Cisplatin. Furthermore, there is an officially stated increased risk of bruising and bleeding when taken alongside anticoagulant or antiplatelet drugs. Regular consumption of alcohol is documented to impair the overall success of treatment with Alatab, establishing specific regulatory constraints for its use.

Mechanism of Action

How Alatab Works

Alatab's mechanism of action is based on the dual functionality of Thioctic Acid (Alpha-Lipoic Acid) as a chemical antioxidant and a metabolic co-factor. This profile facilitates the modulation of defined physiological processes through direct molecular interaction.


H2 — ALA/ DHLA Redox Cycling and Antioxidant Regeneration

The core mechanism involves the reversible chemical conversion of Thioctic Acid (ALA) to Dihydrolipoic Acid (DHLA), which forms a redox couple that directly neutralizes damaging Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). This direct scavenging is complemented by the critical ability of DHLA to regenerate the body's major antioxidants, such as Glutathione, Vitamin C, and Vitamin E, reinforcing the cellular defense system and maintaining the structural stability of biomolecules within tissues susceptible to oxidation.


H2 — Co-Factor Role in Mitochondrial Energy Metabolism

Thioctic Acid is an essential co-factor for crucial enzyme complexes within the mitochondria, particularly the Pyruvate Dehydrogenase Complex and the alpha-Ketoglutarate Dehydrogenase Complex. By supporting these key enzymes, the drug optimizes the efficiency of the Krebs Cycle and electron transport, which results in the enhanced rate of ATP synthesis. This mechanism directly contributes to maintaining cellular energy reserves necessary for high-demand metabolic processes, such as neuronal signaling.


H2 — Modulation of Inflammatory and Neuronal Signaling

The molecule acts as an indirect modulator of inflammatory cascades by inhibiting the activation of the transcription factor NF-kappa B, thereby facilitating the suppression of genetic signals that regulate inflammatory responses. Additionally, it influences peripheral neuronal excitability by modulating ion channel activity, which facilitates a more regulated activity pattern within neuronal pathways. These combined actions result in the maintenance of cellular microenvironmental balance and a decrease in molecular stressor activity.

Dosage and Administration Information

Alatab treatment follows a standardized phased regimen involving two distinct administration routes for its 600 mg dose. The overall administration protocol begins with a short, intensive course using the intravenous (IV) infusion form, and subsequently transitions to the oral film tablet for long-term continuation. The standard adult usage regimen specifies that the drug is administered once daily in both the initial and maintenance phases.

The initial intravenous course is typically administered for a duration of 2 to 4 weeks. This IV administration requires adherence to specific procedural constraints: the 600 mg dose must be infused slowly over a period of at least 30 minutes. Additionally, the solution is required to be protected from light and used immediately upon preparation to maintain its integrity.

The established protocol includes specific instructions for certain patient populations. Use is not recommended for children and adolescents due to a lack of sufficient clinical experience in this age range. Furthermore, in the context of liver function, the medicine must be administered with caution in cases of hepatic impairment. The protocol also includes the instruction that a patient must not take a double dose to make up for a missed administration. This protocol establishes the necessary steps and constraints for the standardized use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alatab (Thioctic Acid)


Evidence for Use in Distressing Sensory Symptoms

The research examined how the active ingredient in Alatab was studied for outcomes related to physical discomfort during periods of heightened symptom activity. Scientists organized large, controlled studies, primarily Randomized Controlled Trials (RCTs), that focused on adults with Type 1 or Type 2 Diabetes who were experiencing mild to moderate nerve damage symptoms (Diabetic Peripheral Neuropathy or DSPN). These trials monitored how patient-reported outcomes describing perceived discomfort changed over defined time intervals. Research described patterns observed in the short-term treatment phase, particularly with the intravenous (IV) formulation.

The evidence for the oral tablet form, however, was associated with limitations. Long-term effects are not fully established regarding the compound's association with objective signs of nerve function, such as measured changes in nerve conduction speed. The findings were mixed when research examined the progression of objective nerve deficits over extended treatment periods.


Research on Metabolic Parameters and Oxidative Stress

Beyond nerve symptoms, research has explored the active ingredient in studies focusing on outcomes monitoring physiological strain or stress. These studies, often smaller in scale and shorter in duration, was observed in adults with Type 2 diabetes or conditions related to metabolic imbalance. The research primarily examined surrogate endpoints—measures that may not directly reflect major clinical outcomes—such as changes in fasting blood sugar, Hemoglobin A1c ( HbA1c), and cholesterol levels.

In these contexts, evidence is limited regarding the clinical significance of these measured changes in metabolic parameters. Data are still emerging, and evidence quality varies across studies examining these metabolic markers. Its long-term association with major clinical events related to diabetes or metabolic syndrome is not fully established.


What is Still Uncertain About the Research

Several key areas of uncertainty have been identified by scientific reviewers. A major gap is the lack of a consistent picture regarding the effect of the oral formulation on objective nerve impairment over many years; long-term effects are not fully established. Furthermore, evidence quality varies across studies due to differences in design, dosage, and patient selection. This contributes to uncertainty remaining low when researchers integrate results, highlighting that research is ongoing to provide clearer insights into these remaining questions.

Key Studies & References

  1. Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review
  2. Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) (NATHAN1) (Clinical Trial Record)

Frequently Asked Questions (FAQ)

Common questions about Alatab (FAQ)


Q: How long does it usually take to feel the benefits of Alatab?

A: Studies examining the active ingredient, Thioctic Acid, were primarily focused on the short-term treatment phase, especially with the initial intravenous (IV) formulation. Information on the long-term effects of the oral treatment is not fully established in regulatory research documents.


Q: Will I need to take Alatab for a long time, or is it a short course of treatment?

A: According to official product information, the treatment regimen typically starts with a short, intensive course using the intravenous (IV) formulation. Following this initial period, patients are transitioned to the oral film tablet form, which is intended for long-term continuation or maintenance.


Q: What is the difference between R-lipoic acid and the form in Alatab?

A: The active ingredient in Alatab is Thioctic Acid. While the R-enantiomer (R-lipoic acid) is the form naturally synthesized by the body, the compound used in this medicine is typically a synthetic, racemic drug mixture. Official documents recognize both forms for their function as an antioxidant.


Q: Does Alatab help with fatigue or overall energy levels?

A: The drug's mechanism involves optimizing the efficiency of key metabolic pathways, which can contribute to maintaining cellular energy reserves (via ATP synthesis) necessary for high-demand processes. This information is based on the known cellular function of the active ingredient.


Q: What should I do if I notice a change in my coordination while on Alatab?

A: Changes in coordination are reported as an adverse reaction affecting the Nervous System. If you notice any serious or persistent changes, it is important to contact a healthcare professional to review your treatment.


Q: Is Alatab a prescription medicine or an over-the-counter supplement?

A: Alatab is a commercial pharmaceutical preparation containing Thioctic Acid. It holds an official regulatory drug label and is therefore classified as a prescribed medicine rather than an over-the-counter supplement.


Q: Is Alatab considered an antioxidant?

A: Yes, Alatab’s active ingredient, Thioctic Acid (Alpha-Lipoic Acid), is classified both as a vitamin-like substance and as a potent antioxidant agent. Its core pharmacological purpose is to support the body’s natural defenses against cellular damage from oxidative stress.


Q: How is Alatab different from a standard B vitamin supplement?

A: Alatab contains Thioctic Acid, which belongs to a pharmacological group known as vitamin-like substances. While it shares functional similarities with B-complex vitamins, particularly in its role in mitochondrial energy production, it is chemically distinct from standard B vitamin supplements.


Q: Is it normal to feel mild stomach discomfort when first starting Alatab?

A: Gastrointestinal issues, such as nausea and diarrhea, are listed as common side effects in the official safety information. Regulatory reports indicate that gastrointestinal disturbances may be more common during the initial phase of therapy.


Q: What kinds of food interactions should I be aware of when taking Alatab?

A: Official prescribing information indicates that the administration of Alatab should be separated in time from the intake of iron preparations or other metal-containing compounds. This is done to ensure the adequate absorption and effectiveness of Alatab.


Q: Can Alatab be used if I have a history of thyroid problems?

A: Regulatory information indicates that the drug may decrease how well thyroid hormone works in the body. If Alatab is co-administered with thyroid medications, careful monitoring of thyroid function may be necessary.


Q: Is Alatab primarily a treatment or a supplement?

A: Alatab is a commercial pharmaceutical preparation with an official drug label. Therefore, it is classified and regulated as a drug (or medicine) intended for therapeutic use, not solely as a dietary supplement.


Q: Does Alatab affect iron levels in the body?

A: Thioctic Acid is a chelating agent, meaning it can bind to metal ions like iron. This chemical property is why simultaneous intake with iron preparations is avoided, as it can reduce the absorption and effectiveness of Alatab.


Q: Are allergic reactions to Alatab common, and what are the signs?

A: Official safety data lists serious reactions, such as Anaphylaxis (severe systemic allergic reaction) and Angioedema (swelling), as rare adverse events. The medicine is contraindicated (should not be used) for anyone with a known hypersensitivity or allergy to the active substance or its ingredients.

How should Alatab be stored and disposed of?

How to Store and Dispose of Alatab?

The storage and disposal of Alatab (Thioctic Acid) must adhere strictly to official regulatory requirements to ensure product integrity and environmental safety.


Storage Conditions

Alatab must be kept in its original container and stored in a cool, dry place. The medicine must be protected from light, as the active substance is photosensitive. Containers must be kept tightly closed when not in use. As a mandatory safety rule, the product must be stored out of the reach of children.


Disposal Requirements

Disposal instructions require that unused or expired Alatab be discarded at an approved waste disposal plant or a special waste collection point. It is explicitly required not to empty the product into drains or other waterways to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alatab found in:

A-Z Index: